Search

Your search keyword '"Minderman, Hans"' showing total 326 results
Start Over Author "Minderman, Hans"
326 results on '"Minderman, Hans"'

1. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study

Author

McCarthy, Philip L., Attwood, Kristopher M., Liu, Xiaojun, Chen, George L., Minderman, Hans, Alousi, Amin, Bashey, Asad, Lowsky, Robert, Miklos, David B., Hansen, John, Westervelt, Peter, Yanik, Gregory, Waller, Edmund K., Howard, Alan, Blazar, Bruce R., Wallace, Paul K., Reshef, Ran, Horowitz, Mary M., Maziarz, Richard T., Levine, John E., and Mohammadpour, Hemn

Published
2024
Full Text
View/download PDF

2. Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).

Author

Babiker, Hani, Borazanci, Erkut, Subbiah, Vivek, Agarwala, Sanjiv, Algazi, Alain, Schachter, Jacob, Lotem, Michael, Maurice-Dror, Corinne, Hendler, Daniel, Rahimian, Shah, Minderman, Hans, Haymaker, Cara, Mahadevan, Daruka, Bernatchez, Chantale, Murthy, Ravi, Hultsch, Rolf, Kaplan, Nadia, Woodhead, Gregory, Hennemeyer, Charles, Chunduru, Srinivas, Anderson, Peter, Diab, Adi, and Puzanov, Igor

Subjects
Humans, Toll-Like Receptor 9, Antigen Presentation, Neoplasms, Melanoma, Cohort Studies, Skin Neoplasms, Tumor Microenvironment
Abstract

PURPOSE: Tilsotolimod is an investigational synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models. The ILLUMINATE-101 phase I study explored the safety, dose, efficacy, and immune effects of intratumoral (it) tilsotolimod monotherapy in multiple solid tumors. PATIENTS AND METHODS: Patients with a diagnosis of refractory cancer not amenable to curative therapies received tilsotolimod in doses escalating from 8 to 32 mg into a single lesion at weeks 1, 2, 3, 5, 8, and 11. Additional patients with advanced malignant melanoma were enrolled into an expansion cohort at the 8 mg dose. Objectives included characterizing the safety, establishing the dose, efficacy, and immunologic assessment. Blood samples and tumor biopsies of injected and noninjected lesions were obtained at baseline and 24 hours after treatment for immune analyses. RESULTS: Thirty-eight and 16 patients were enrolled into the dose escalation and melanoma expansion cohorts, respectively. Deep visceral injections were conducted in 91% of patients. No dose-limiting toxicities (DLT) or grade 4 treatment-related adverse events were observed. Biopsies 24 hours after treatment demonstrated an increased IFN pathway signature and dendritic cell maturation. Immunologic profiling revealed upregulation of IFN-signaling genes and modulation of genes for checkpoint proteins. In the dose escalation cohort, 12 (34%) of 35 evaluable patients achieved a best overall response rate (ORR) of stable disease (SD), whereas 3 (19%) of 16 evaluable patients in the melanoma cohort achieved stable disease. CONCLUSIONS: Overall, tilsotolimod monotherapy was generally well tolerated and induced rapid, robust alterations in the tumor microenvironment. See related commentary by Punekar and Weber, p. 5007.

Published
2022

4. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study

Author

McCarthy, Philip L., primary, Attwood, Kristopher M., additional, Liu, Xiaojun, additional, Chen, George L., additional, Minderman, Hans, additional, Alousi, Amin, additional, Bashey, Asad, additional, Lowsky, Robert, additional, Miklos, David B., additional, Hansen, John, additional, Westervelt, Peter, additional, Yanik, Gregory, additional, Waller, Edmund K., additional, Howard, Alan, additional, Blazar, Bruce R., additional, Wallace, Paul K., additional, Reshef, Ran, additional, Horowitz, Mary M., additional, Maziarz, Richard T., additional, Levine, John E., additional, and Mohammadpour, Hemn, additional

Published
2023
Full Text
View/download PDF

5. Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx

Author

Gandhi, Shipra, primary, Opyrchal, Mateusz, additional, Grimm, Melissa J, additional, Slomba, Ronald T, additional, Kokolus, Kathleen M, additional, Witkiewicz, Agnieszka, additional, Attwood, Kristopher, additional, Groman, Adrienne, additional, Williams, Lauren, additional, Tarquini, Mary Lynne, additional, Wallace, Paul K, additional, Soh, Kah Teong, additional, Minderman, Hans, additional, Maguire, Orla, additional, O’Connor, Tracey L, additional, Early, Amy P, additional, Levine, Ellis G, additional, and Kalinski, Pawel, additional

Published
2023
Full Text
View/download PDF

6. NK Receptors Replace CD28 As the Dominant Source of Signal 2 for Cognate Recognition of Cancer Cells by TAA-specific Effector CD8+ T Cells

Author

Kalinski, Pawel, primary, Dong, Bowen, additional, Obermajer, Natasa, additional, Tsuji, Takemasa, additional, Matsuzaki, Junko, additional, Bonura, Cindy, additional, Withers, Henry, additional, Long, Mark, additional, Chavel, Colin, additional, Olejniczak, Scott, additional, Minderman, Hans, additional, Edwards, Robert, additional, Storkus, Walter, additional, and Romero, Pedro, additional

Published
2023
Full Text
View/download PDF

11. NADPH oxidase limits innate immune responses in the lungs in mice.

Author

Segal, Brahm H, Han, Wei, Bushey, Jennifer J, Joo, Myungsoo, Bhatti, Zahida, Feminella, Joy, Dennis, Carly G, Vethanayagam, R Robert, Yull, Fiona E, Capitano, Maegan, Wallace, Paul K, Minderman, Hans, Christman, John W, Sporn, Michael B, Chan, Jefferson, Vinh, Donald C, Holland, Steven M, Romani, Luigina R, Gaffen, Sarah L, Freeman, Michael L, and Blackwell, Timothy S

Subjects
Lung, Macrophages, Animals, Mice, Granulomatous Disease, Chronic, Inflammation, NF-kappa B, Membrane Glycoproteins, Cytokines, Gene Expression Regulation, Enzymologic, Oxidation-Reduction, NF-E2-Related Factor 2, Immunity, Innate, NADPH Oxidase 2, NADPH Oxidases, Granulomatous Disease, Chronic, NADPH Oxidase, Gene Expression Regulation, Enzymologic, Immunity, Innate, General Science & Technology
Abstract

BackgroundChronic granulomatous disease (CGD), an inherited disorder of the NADPH oxidase in which phagocytes are defective in generating superoxide anion and downstream reactive oxidant intermediates (ROIs), is characterized by recurrent bacterial and fungal infections and by excessive inflammation (e.g., inflammatory bowel disease). The mechanisms by which NADPH oxidase regulates inflammation are not well understood.Methodology/principal findingsWe found that NADPH oxidase restrains inflammation by modulating redox-sensitive innate immune pathways. When challenged with either intratracheal zymosan or LPS, NADPH oxidase-deficient p47(phox-/-) mice and gp91(phox)-deficient mice developed exaggerated and progressive lung inflammation, augmented NF-kappaB activation, and elevated downstream pro-inflammatory cytokines (TNF-alpha, IL-17, and G-CSF) compared to wildtype mice. Replacement of functional NADPH oxidase in bone marrow-derived cells restored the normal lung inflammatory response. Studies in vivo and in isolated macrophages demonstrated that in the absence of functional NADPH oxidase, zymosan failed to activate Nrf2, a key redox-sensitive anti-inflammatory regulator. The triterpenoid, CDDO-Im, activated Nrf2 independently of NADPH oxidase and reduced zymosan-induced lung inflammation in CGD mice. Consistent with these findings, zymosan-treated peripheral blood mononuclear cells from X-linked CGD patients showed impaired Nrf2 activity and increased NF-kappaB activation.Conclusions/significanceThese studies support a model in which NADPH oxidase-dependent, redox-mediated signaling is critical for termination of lung inflammation and suggest new potential therapeutic targets for CGD.

Published
2010

12. Supplementary Table 1 from Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1

Author

Thomas, Lawrence J., primary, Vitale, Laura, primary, O'Neill, Thomas, primary, Dolnick, Ree Y., primary, Wallace, Paul K., primary, Minderman, Hans, primary, Gergel, Lauren E., primary, Forsberg, Eric M., primary, Boyer, James M., primary, Storey, James R., primary, Pilsmaker, Catherine D., primary, Hammond, Russell A., primary, Widger, Jenifer, primary, Sundarapandiyan, Karuna, primary, Crocker, Andrea, primary, Marsh, Henry C., primary, and Keler, Tibor, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 1 from Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1

Author

Thomas, Lawrence J., primary, Vitale, Laura, primary, O'Neill, Thomas, primary, Dolnick, Ree Y., primary, Wallace, Paul K., primary, Minderman, Hans, primary, Gergel, Lauren E., primary, Forsberg, Eric M., primary, Boyer, James M., primary, Storey, James R., primary, Pilsmaker, Catherine D., primary, Hammond, Russell A., primary, Widger, Jenifer, primary, Sundarapandiyan, Karuna, primary, Crocker, Andrea, primary, Marsh, Henry C., primary, and Keler, Tibor, primary

Published
2023
Full Text
View/download PDF

17. Data from Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1

Author

Thomas, Lawrence J., primary, Vitale, Laura, primary, O'Neill, Thomas, primary, Dolnick, Ree Y., primary, Wallace, Paul K., primary, Minderman, Hans, primary, Gergel, Lauren E., primary, Forsberg, Eric M., primary, Boyer, James M., primary, Storey, James R., primary, Pilsmaker, Catherine D., primary, Hammond, Russell A., primary, Widger, Jenifer, primary, Sundarapandiyan, Karuna, primary, Crocker, Andrea, primary, Marsh, Henry C., primary, and Keler, Tibor, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Data from Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)

Author

Babiker, Hani, primary, Borazanci, Erkut, primary, Subbiah, Vivek, primary, Agarwala, Sanjiv, primary, Algazi, Alain, primary, Schachter, Jacob, primary, Lotem, Michael, primary, Maurice-Dror, Corinne, primary, Hendler, Daniel, primary, Rahimian, Shah, primary, Minderman, Hans, primary, Haymaker, Cara, primary, Mahadevan, Daruka, primary, Bernatchez, Chantale, primary, Murthy, Ravi, primary, Hultsch, Rolf, primary, Kaplan, Nadia, primary, Woodhead, Gregory, primary, Hennemeyer, Charles, primary, Chunduru, Srinivas, primary, Anderson, Peter M., primary, Diab, Adi, primary, and Puzanov, Igor, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 1 from Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

Author

Fountzilas, Christos, primary, Bajor, David L., primary, Mukherjee, Sarbajit, primary, Saltzman, Joel, primary, Witkiewicz, Agnieszka K., primary, Maguire, Orla, primary, Minderman, Hans, primary, Nambiar, Ram, primary, Rosenheck, Hanna R., primary, Knudsen, Erik S., primary, Muhitch, Jason B., primary, Abrams, Scott I., primary, Wang, Chong, primary, Hutson, Alan D., primary, Attwood, Kristopher, primary, Hicks, Karen A., primary, Jurcevic, Jennifer A., primary, Kalinski, Pawel, primary, Iyer, Renuka, primary, and Boland, Patrick M., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 2 from Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

Author

Fountzilas, Christos, primary, Bajor, David L., primary, Mukherjee, Sarbajit, primary, Saltzman, Joel, primary, Witkiewicz, Agnieszka K., primary, Maguire, Orla, primary, Minderman, Hans, primary, Nambiar, Ram, primary, Rosenheck, Hanna R., primary, Knudsen, Erik S., primary, Muhitch, Jason B., primary, Abrams, Scott I., primary, Wang, Chong, primary, Hutson, Alan D., primary, Attwood, Kristopher, primary, Hicks, Karen A., primary, Jurcevic, Jennifer A., primary, Kalinski, Pawel, primary, Iyer, Renuka, primary, and Boland, Patrick M., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 3 from Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

Author

Fountzilas, Christos, primary, Bajor, David L., primary, Mukherjee, Sarbajit, primary, Saltzman, Joel, primary, Witkiewicz, Agnieszka K., primary, Maguire, Orla, primary, Minderman, Hans, primary, Nambiar, Ram, primary, Rosenheck, Hanna R., primary, Knudsen, Erik S., primary, Muhitch, Jason B., primary, Abrams, Scott I., primary, Wang, Chong, primary, Hutson, Alan D., primary, Attwood, Kristopher, primary, Hicks, Karen A., primary, Jurcevic, Jennifer A., primary, Kalinski, Pawel, primary, Iyer, Renuka, primary, and Boland, Patrick M., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 4 from Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

Author

Fountzilas, Christos, primary, Bajor, David L., primary, Mukherjee, Sarbajit, primary, Saltzman, Joel, primary, Witkiewicz, Agnieszka K., primary, Maguire, Orla, primary, Minderman, Hans, primary, Nambiar, Ram, primary, Rosenheck, Hanna R., primary, Knudsen, Erik S., primary, Muhitch, Jason B., primary, Abrams, Scott I., primary, Wang, Chong, primary, Hutson, Alan D., primary, Attwood, Kristopher, primary, Hicks, Karen A., primary, Jurcevic, Jennifer A., primary, Kalinski, Pawel, primary, Iyer, Renuka, primary, and Boland, Patrick M., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 5 from Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

Author

Fountzilas, Christos, primary, Bajor, David L., primary, Mukherjee, Sarbajit, primary, Saltzman, Joel, primary, Witkiewicz, Agnieszka K., primary, Maguire, Orla, primary, Minderman, Hans, primary, Nambiar, Ram, primary, Rosenheck, Hanna R., primary, Knudsen, Erik S., primary, Muhitch, Jason B., primary, Abrams, Scott I., primary, Wang, Chong, primary, Hutson, Alan D., primary, Attwood, Kristopher, primary, Hicks, Karen A., primary, Jurcevic, Jennifer A., primary, Kalinski, Pawel, primary, Iyer, Renuka, primary, and Boland, Patrick M., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 1 from Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

Author

Fountzilas, Christos, primary, Bajor, David L., primary, Mukherjee, Sarbajit, primary, Saltzman, Joel, primary, Witkiewicz, Agnieszka K., primary, Maguire, Orla, primary, Minderman, Hans, primary, Nambiar, Ram, primary, Rosenheck, Hanna R., primary, Knudsen, Erik S., primary, Muhitch, Jason B., primary, Abrams, Scott I., primary, Wang, Chong, primary, Hutson, Alan D., primary, Attwood, Kristopher, primary, Hicks, Karen A., primary, Jurcevic, Jennifer A., primary, Kalinski, Pawel, primary, Iyer, Renuka, primary, and Boland, Patrick M., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 3 from Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

Author

Fountzilas, Christos, primary, Bajor, David L., primary, Mukherjee, Sarbajit, primary, Saltzman, Joel, primary, Witkiewicz, Agnieszka K., primary, Maguire, Orla, primary, Minderman, Hans, primary, Nambiar, Ram, primary, Rosenheck, Hanna R., primary, Knudsen, Erik S., primary, Muhitch, Jason B., primary, Abrams, Scott I., primary, Wang, Chong, primary, Hutson, Alan D., primary, Attwood, Kristopher, primary, Hicks, Karen A., primary, Jurcevic, Jennifer A., primary, Kalinski, Pawel, primary, Iyer, Renuka, primary, and Boland, Patrick M., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 2 from Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

Author

Fountzilas, Christos, primary, Bajor, David L., primary, Mukherjee, Sarbajit, primary, Saltzman, Joel, primary, Witkiewicz, Agnieszka K., primary, Maguire, Orla, primary, Minderman, Hans, primary, Nambiar, Ram, primary, Rosenheck, Hanna R., primary, Knudsen, Erik S., primary, Muhitch, Jason B., primary, Abrams, Scott I., primary, Wang, Chong, primary, Hutson, Alan D., primary, Attwood, Kristopher, primary, Hicks, Karen A., primary, Jurcevic, Jennifer A., primary, Kalinski, Pawel, primary, Iyer, Renuka, primary, and Boland, Patrick M., primary

Published
2023
Full Text
View/download PDF

36. Short-Term Storage of Mobilized Peripheral Blood Stem Cells in a Closed System Changes the Microenvironment and May Affect the Quantity of CD34+ and CD34+CD38-CD45RA-CD90+ Cells

Author

Elshoury, Amro, primary, Maguire, Orla, additional, Conway, Alexis, additional, Tario, Joseph, additional, Soh, Kah Teong, additional, Ross, Maureen, additional, Hahn, Theresa, additional, Becker, Joanne, additional, Wallace, Paul, additional, McCarthy, Philip L., additional, Minderman, Hans, additional, and Chen, George L., additional

Published
2022
Full Text
View/download PDF

40. Comparison of P‐glycoprotein function in peripheral blood mononuclear cells ex vivo in stable Black and White male and female kidney transplant recipients.

Author

Tornatore, Kathleen M., Attwood, Kris, Brazeau, Daniel, Sprowl, Jason, Chang, Shirley, Gundroo, Aijaz, Minderman, Hans, and Venuto, Rocco C.

Subjects
MONONUCLEAR leukocytes, BLACK men, KIDNEY transplantation, P-glycoprotein, ATP-binding cassette transporters, FEMALES
Abstract

Kidney allograft survival remains poorer in Black compared to White recipients due to racial differences in calcineurin inhibitor (CNI) pharmacology. P‐glycoprotein (P‐gp), an ABC efflux transporter expressed in peripheral blood mononuclear cells (PBMCs), modulates CNI pharmacokinetics and intracellular pharmacology. This study investigated P‐gp function in PBMC ex vivo at 0 (trough), 4, 8, and 12 h in stable Black and White male and female kidney transplant recipients (n = 67) receiving tacrolimus and mycophenolic acid. Tacrolimus doses were adjusted to troughs of 4–10 ng/ml. P‐gp function was quantified with flow cytometric measurement of cyclosporine (CYA; 2.5 μM)‐reversible efflux of P‐gp substrate, 3,3′‐Diethyloxacarbocyanine iodide by determining the percentage change of mean fluorescent intensity (MFI) with CYA (% ΔMFI). The composite parameter of area under the concentration versus time (AUC)0–12h % ΔMFI estimated P‐gp function. Data analysis examined race, sex, and race‐sex associations to P‐gp function. A secondary aim analyzed ABCB1 genotypes: 1236C>T (rs1128503), 2677G>T/A (rs2032582), 3435C>T (rs1045642), and P‐gp function. P‐gp function (% ΔMFI) was higher in White patients at troughs (p = 0.031) compared to Black counterparts with similar trends at 4 and 8 h. Reduced AUC0–12h % ΔMFI was noted in Black recipients (N = 32) compared with Whites (N = 35, p = 0.029) with notable pairwise adjusted differences between Black and White women (p = 0.021). Higher AUC0–12h % ΔMFI was associated with ABCB1 2677 TT compared to GG variants (p = 0.035). The AUC0–12h % ΔMFI was greater in White than Black subjects. P‐gp function was higher at troughs in White subjects and differed between race‐sex groups. P‐gp function in PBMC may influence intracellular tacrolimus exposure and inter‐relating pharmacodynamic responses which may support race and sex pharmacologic differences. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

Author

Fountzilas, Christos, primary, Bajor, David L., additional, Mukherjee, Sarbajit, additional, Saltzman, Joel, additional, Witkiewicz, Agnieszka K., additional, Maguire, Orla, additional, Minderman, Hans, additional, Nambiar, Ram, additional, Rosenheck, Hanna R., additional, Knudsen, Erik S., additional, Muhitch, Jason B., additional, Abrams, Scott I., additional, Wang, Chong, additional, Hutson, Alan D., additional, Attwood, Kristopher, additional, Hicks, Karen A., additional, Jurcevic, Jennifer A., additional, Kalinski, Pawel, additional, Iyer, Renuka, additional, and Boland, Patrick M., additional

Published
2021
Full Text
View/download PDF

43. Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation

Author

Mistarz, Anna, primary, Graczyk, Matthew, additional, Winkler, Marta, additional, Singh, Prashant K., additional, Cortes, Eduardo, additional, Miliotto, Anthony, additional, Liu, Song, additional, Long, Mark, additional, Yan, Li, additional, Stablewski, Aimee, additional, O’Loughlin, Kieran, additional, Minderman, Hans, additional, Odunsi, Kunle, additional, Rokita, Hanna, additional, McGray, A.J. Robert, additional, Zsiros, Emese, additional, and Kozbor, Danuta, additional

Published
2021
Full Text
View/download PDF

44. Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments

Author

Bhatta, Maulasri, primary, Shenoy, Gautam N, additional, Loyall, Jenni L, additional, Gray, Brian D, additional, Bapardekar, Meghana, additional, Conway, Alexis, additional, Minderman, Hans, additional, Kelleher Jr, Raymond J, additional, Carreno, Beatriz M, additional, Linette, Gerald, additional, Shultz, Leonard D, additional, Odunsi, Kunle, additional, Balu-Iyer, Sathy V, additional, Pak, Koon Yan, additional, and Bankert, Richard B, additional

Published
2021
Full Text
View/download PDF

45. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models

Author

Oba, Takaaki, primary, Makino, Kenichi, additional, Kajihara, Ryutaro, additional, Yokoi, Toshihiro, additional, Araki, Ryoko, additional, Abe, Masumi, additional, Minderman, Hans, additional, Chang, Alfred E, additional, Odunsi, Kunle, additional, and Ito, Fumito, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results